Form CDC 57.140 CDC 57.140 Urinary Tract Infection (UTI) for LTCF

The National Healthcare Safety Network (NHSN)

57.140_UTI_LTCF_BLANK

57.140 Urinary Tract Infection (UTI) for LTCF

OMB: 0920-0666

Document [docx]
Download: docx | pdf

Form Approved

OMB No. 0920-0666

Exp. Date: xx/xxx/xxxx

www.cdc.gov/nhsn

Urinary Tract Infection (UTI) for LTCF

Page 1 of 4

*required for saving

*Facility ID:

Event #:

*Resident ID:


Medicare number (or comparable railroad insurance number):

Resident Name, Last:

First:

Middle:

*Gender: M F Other

*Date of Birth: ___/___/____

Ethnicity (specify):

Race (specify):




*Date of First Admission to Facility: __/__/____

*Date of Current Admission to Facility: __/__/____

*Event Type: UTI

*Date of Event: __/__/____

*Resident Care Location: __________________________

*Primary Resident Service Type: (check one)

Long-term general nursing

Long-term dementia

Long-term psychiatric

Skilled nursing/Short-term rehab (subacute)

Ventilator

Bariatric

Hospice/Palliative

*Has resident been transferred from an acute care facility to your facility in the past 4 weeks?

Yes

No

If Yes, date of last transfer from acute care to your facility: __/__/____

If Yes, did the resident have an indwelling urinary catheter at the time of transfer to your facility?

Yes

No

*Indwelling Urinary Catheter status at time of event onset (check one):

In place

Removed within last 2 calendar days

Not in place

If indwelling urinary catheter status in place or removed within last 2 calendar days:


Site where indwelling urinary catheter Inserted (check one):

Your facility

Acute care hospital

Other

Unknown


Date of indwelling urinary catheter Insertion: ___/___/_____

If indwelling urinary catheter not in place, was another urinary device type present at the time of event onset?

Yes

No


If Yes, other device type:

Suprapubic

Condom (males only)

Intermittent straight catheter

Event Details

*Specify Criteria Used: (check all that apply)

Laboratory & Diagnostic Testing

Signs & Symptoms

Fever: Single temperature ≥ 37.8°C (>100°F), or > 37.2°C (>99°F) on repeated occasions, or an increase of >1.1°C (>2°F) over baseline

Positive urine culture with no more than 2 species of microorganisms, at least one of which is a bacterium of ≥ 105 CFU/ml

Rigors

New onset hypotension

New onset confusion/functional decline


Acute pain, swelling, or tenderness of the testes, epididymis, or prostate

Acute dysuria

Purulent drainage at catheter insertion site


New and/or marked increase in (check all that apply):

Urgency

Costovertebral angle pain or tenderness

Leukocytosis (> 14,000 cells/mm3), or Left shift (> 6% or 1,500 bands/mm3)

Frequency

Suprapubic tenderness

Incontinence

Visible (gross) hematuria

Positive blood culture with 1 matching organism in urine culture

*Specific Event (Check one):

Symptomatic UTI (SUTI)

Symptomatic CA-UTI (CA-SUTI)

Asymptomatic Bacteremic UTI (ABUTI)

Secondary Bloodstream Infection: Yes No

Died within 7 days of date of event: Yes No

*Transfer to acute care facility within 7 days: Yes No


*Pathogens identified: Yes No

*If Yes, specify on page 2

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).


Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666). CDC 57.140 (Front) r3 v9.2

Urinary Tract Infection (UTI) for LTCF

Page 2 of 4

Pathogen #

Gram-positive Organisms


_______


Staphylococcus coagulase-negative


VANC

S I R N

(specify species if available):

____________


_______


____Enterococcus faecium


____Enterococcus faecalis

____Enterococcus spp.

(Only those not identified to the species level)


DAPTO

S NS N


GENTHL§

S R N


LNZ

S I R N


VANC

S I R N




_______


Staphylococcus aureus


CIPRO/LEVO/MOXI

S I R N


CLIND

S I R N


DAPTO

S NS N


DOXY/MINO

S I R N


ERYTH

S I R N


GENT

S I R N


LNZ

S R N


OX/CEFOX/METH

S I R N


RIF

S I R N


TETRA

S I R N


TIG

S NS N


TMZ

S I R N


VANC

S I R N


Pathogen #

Gram-negative Organisms


_______


Acinetobacter

(specify species)

____________


AMK

S I R N


AMPSUL

S I R N


AZT

S I R N


CEFEP

S I R N


CEFTAZ

S I R N


CIPRO/LEVO

S I R N


COL/PB

S I R N


GENT

S I R N


IMI

S I R N



MERO/DORI

S I R N


PIP/PIPTAZ

S I R N


TETRA/DOXY/MINO

S I R N


TMZ

S I R N


TOBRA

S I R N



_______


Escherichia coli


AMK

S I R N


AMP

S I R N


AMPSUL/AMXCLV

S I R N


AZT

S I R N


CEFAZ

S I R N


CEFEP

S I/S-DD R N


CEFOT/CEFTRX

S I R N


CEFTAZ

S I R N


CEFUR

S I R N


CEFOX/CETET

S I R N


CIPRO/LEVO/MOXI

S I R N


COL/PB

S R N


ERTA

S I R N


GENT

S I R N


IMI

S I R N


MERO/DORI

S I R N


PIPTAZ

S I R N


TETRA/DOXY/MINO

S I R N


TIG

S I R N


TMZ

S I R N


TOBRA

S I R N



_______


Enterobacter

(specify species)

____________


AMK

S I R N


AMP

S I R N


AMPSUL/AMXCLV

S I R N


AZT

S I R N


CEFAZ

S I R N


CEFEP

S I/S-DD R N


CEFOT/CEFTRX

S I R N


CEFTAZ

S I R N


CEFUR

S I R N


CEFOX/CETET

S I R N


CIPRO/LEVO/MOXI

S I R N


COL/PB

S R N


ERTA

S I R N


GENT

S I R N


IMI

S I R N


MERO/DORI

S I R N


PIPTAZ

S I R N


TETRA/DOXY/MINO

S I R N


TIG

S I R N


TMZ

S I R N


TOBRA

S I R N



_______


____Klebsiella

pneumonia


____Klebsiella

oxytoca



AMK

S I R N


AMP

S I R N


AMPSUL/AMXCLV

S I R N


AZT

S I R N


CEFAZ

S I R N


CEFEP

S I/S-DD R N


CEFOT/CEFTRX

S I R N


CEFTAZ

S I R N


CEFUR

S I R N


CEFOX/CETET

S I R N


CIPRO/LEVO/MOXI

S I R N


COL/PB

S R N


ERTA

S I R N


GENT

S I R N


IMI

S I R N


MERO/DORI

S I R N


PIPTAZ

S I R N


TETRA/DOXY/MINO

S I R N


TIG

S I R N


TMZ

S I R N


TOBRA

S I R N





Urinary Tract Infection (UTI) for LTCF

Page 3 of 4

Pathogen #

Gram-negative Organisms (continued)


_______


Pseudomonas aeruginosa


AMK

S I R N


AZT

S I R N


CEFEP

S I R N


CEFTAZ

S I R N


CIPRO/LEVO

S I R N


COL/PB

S I R N


GENT

S I R N


IMI

S I R N



MERO/DORI

S I R N


PIP/PIPTAZ

S I R N


TOBRA

S I R N

Pathogen #

Other Organisms

_______

Organism 1 (specify)

____________


_______Drug 1

S I R N

_______ Drug 2

S I R N

______

Drug 3

S I R N

_______ Drug 4

S I R N

_______Drug 5

S I R N

______ Drug 6

S I R N

______ Drug 7

S I R N

______ Drug 8

S I R N

______ Drug 9

S I R N

_______

Organism 1 (specify)

____________


_______Drug 1

S I R N

_______ Drug 2

S I R N

______

Drug 3

S I R N

_______ Drug 4

S I R N

_______Drug 5

S I R N

______ Drug 6

S I R N

______ Drug 7

S I R N

______ Drug 8

S I R N

______ Drug 9

S I R N

_______

Organism 1 (specify)

____________


_______Drug 1

S I R N

_______ Drug 2

S I R N

______

Drug 3

S I R N

_______ Drug 4

S I R N

_______Drug 5

S I R N

______ Drug 6

S I R N

______ Drug 7

S I R N

______ Drug 8

S I R N

______ Drug 9

S I R N



Result Codes

S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested

§ GENTHL results: S = Susceptible/Synergistic and R = Resistant/Not Synergistic

Clinical breakpoints have not been set by FDA or CLSI, Sensitive and Resistant designations should be based upon epidemiological cutoffs of Sensitive MIC ≤ 2 and Resistant MIC ≥ 4


Drug Codes:




AMK = amikacin

CEFTRX = ceftriaxone

FLUCY = flucytosine

OX = oxacillin

AMP = ampicillin

CEFUR= cefuroxime

GENT = gentamicin

PB = polymyxin B

AMPSUL = ampicillin/sulbactam

CETET= cefotetan

GENTHL = gentamicin –high level test

PIP = piperacillin

AMXCLV = amoxicillin/clavulanic acid

CIPRO = ciprofloxacin

IMI = imipenem

PIPTAZ = piperacillin/tazobactam

ANID = anidulafungin

CLIND = clindamycin

ITRA = itraconazole

RIF = rifampin

AZT = aztreonam

COL = colistin

LEVO = levofloxacin

TETRA = tetracycline

CASPO = caspofungin

DAPTO = daptomycin

LNZ = linezolid

TIG = tigecycline

CEFAZ= cefazolin

DORI = doripenem

MERO = meropenem

TMZ = trimethoprim/sulfamethoxazole

CEFEP = cefepime

DOXY = doxycycline

METH = methicillin

TOBRA = tobramycin

CEFOT = cefotaxime

ERTA = ertapenem

MICA = micafungin

VANC = vancomycin

CEFOX= cefoxitin

ERYTH = erythromycin

MINO = minocycline

VORI = voriconazole

CEFTAZ = ceftazidime

FLUCO = fluconazole

MOXI = moxifloxacin



Urinary Tract Infection (UTI) for LTCF

Page 4 of 4

Custom Fields

Label

Label

______________________

____/____/____

_______________________

____/____/_____

_______________________

_____________

_______________________

______________

_______________________

_____________

_______________________

______________

_________________________

______________

_______________________

______________

_________________________

______________

_______________________

______________

_________________________

______________

_______________________

______________

_________________________

______________

_______________________

______________


Comments
















































File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
File Title57.140_UTI_LTCF
AuthorAmy Schneider;CDC
File Modified0000-00-00
File Created2021-04-12

© 2024 OMB.report | Privacy Policy